About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma | Clinical Trials | Clareo Health

Back to clinical trial search

TERMINATEDPhase 2NCT04365660

18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma

The purpose of this research is to evaluate the study drug, 18F FTC-146, as a positron emission tomography (PET) / computed tomography (CT) radiotracer imaging agent to evaluate tumor status in patien...

Lead sponsor: Davidzon, Guido, M.D.•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Davidzon, Guido, M.D.

Primary Objective: Demonstrate correlation of pre-post reduction in 18F-FTC-146 PET/CT with amount of post-treatment tumor necrosis in newly-diagnosed and treated osteosarcoma patients. Secondary Objective: Demonstrate correlation of pre-post reduction in 18F-FTC-146 PET/CT with amount of post-treatment pain reduction in newly-diagnosed and treated osteosarcoma patients.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients with biopsy proven osteosarcoma requiring local surgical intervention.
•ECOG ≤ 2
•Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

•Chemotherapy in the past 2 months.
•Prior history of allergic reaction to 18F FTC 146.
•Pregnant or nursing

Related studies

RECRUITINGPhase 2

Agnostic Therapy in Rare Solid Tumors

NCT06638931 · Urachal Cancer, Parathyroid Carcinoma, and more

RECRUITINGPhase 1/2

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

NCT06541262 · Neuroblastoma, Ewing Sarcoma, and more

RECRUITINGPhase 1/2

Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma

NCT07479732 · Osteosarcoma, Osteosarcoma Metastatic

Upfront Surgical Resection for Osteosarcoma

NCT06384404 · Osteosarcoma

RECRUITINGPhase 1/2

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

NCT06625190 · Neuroblastoma, Rhabdomyosarcoma, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 14, 2023Terms

Trial snapshot

StatusTERMINATED

PhasePHASE2

Enrollment1

Start dateJan 2021

Last updatedNov 14, 2023

Condition

Locations shown

Stanford University

Stanford, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 14, 2023Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions